ClinicalTrials.gg
CompletedNCT03030183Updated Jul 27, 2022Results posted

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

A Phase 2 interventional study of Zilucoplan (RA101495) in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Ra Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by Ra Pharmaceuticals (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hemoglobinuria, Paroxysmal · United States.

Enrollment
50th of 54
3 · median 53
Started
2017
with 5 others
Phase 2
21 of 68
4 open now
Registered
36th of 68
by date

Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, this one is the 50th largest by enrollment of the 54 interventional ones that give a count, is one of 6 that started in 2017, is one of 21 in phase 2, and was the 36th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

10 of the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Keywords

  • PNH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PNH by flow cytometry
  • Inadequate response to eculizumab defined as having received eculizumab for at least 6 months plus a documented LDH level ≥ 1.5 x the (ULN) and/or the presence of a known C5 mutation conferring resistance to eculizumab

Exclusion criteria

Exclusion Criteria:

  • History of meningococcal disease
  • Current systemic infection or suspicion of active bacterial infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Zilucoplan (RA101495)

    Subjects will receive RA101495 at the dose of 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC

    Drug: Zilucoplan (RA101495)

Interventions

  • 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC

06

What researchers measure

Primary outcomes

  1. Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Levels.

    Change-from-baseline through Week 12 in serum lactate dehydrogenase (LDH) levels

    Time frame: Through Week 12 of the study

Secondary outcomes

  1. Change-from-baseline Bilirubin Values

    Changes from baseline at each of the scheduled postbaseline time-points

    Time frame: Through week 12

  2. Change-from-baseline Total Hemoglobin Values

    Changes from baseline at each of the scheduled postbaseline time-points

    Time frame: Through week 12

  3. Change-from-baseline Free Hemoglobin Values

    Changes from baseline at each of the scheduled postbaseline time-points

    Time frame: Through week 12

  4. Change-from-baseline Haptoglobin Values

    Changes from baseline at each of the scheduled postbaseline time-points

    Time frame: Through week 12

  5. Change-from-baseline Reticulocyte Values

    Changes from baseline at each of the scheduled postbaseline time-points

    Time frame: Through week 12

  6. Change-from-baseline Hemoglobinuria Values

    Changes from baseline at each of the scheduled postbaseline time-points Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10. Where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria.

    Time frame: Through week 12

07

Results

Posted Feb 26, 2020

Participant flow

Participant flow — Overall Study
MilestoneZilucoplan (RA101495)
Started3
Completed3
Not completed0

Outcome measures

PrimaryChange-from-baseline in Serum Lactate Dehydrogenase (LDH) Levels.

Change-from-baseline through Week 12 in serum lactate dehydrogenase (LDH) levels

Time frame:
Through Week 12 of the study
Reported as:
Mean · U/L
Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Levels.
U/LZilucoplan (RA101495)
Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Levels.100.3 ± 128.0
SecondaryChange-from-baseline Bilirubin Values

Changes from baseline at each of the scheduled postbaseline time-points

Time frame:
Through week 12
Reported as:
Mean · umol/L
Change-from-baseline Bilirubin Values
umol/LZilucoplan (RA101495)
Week 1-3.3 ± 5.1
Week 2-4.7 ± 12.0
Week 3-4.3 ± 7.5
Week 4-0.3 ± 2.9
Week 6-6.7 ± 17.5
Week 8-2.3 ± 12.5
Week 10-7.7 ± 14.8
Week 12-2.0 ± 6.2
SecondaryChange-from-baseline Total Hemoglobin Values

Changes from baseline at each of the scheduled postbaseline time-points

Time frame:
Through week 12
Reported as:
Mean · g/L
Change-from-baseline Total Hemoglobin Values
g/LZilucoplan (RA101495)
Week 15.7 ± 4.2
Week 23.3 ± 3.8
Week 30.3 ± 4.0
Week 4-0.3 ± 7.2
Week 60.7 ± 5.8
Week 8-3.3 ± 4.2
Week 102.3 ± 3.1
Week 120.3 ± 2.5
SecondaryChange-from-baseline Free Hemoglobin Values

Changes from baseline at each of the scheduled postbaseline time-points

Time frame:
Through week 12
Reported as:
Number · mg/dL
Change-from-baseline Free Hemoglobin Values
mg/dLZilucoplan (RA101495)
Week 1-145.90
Week 2-140.60
Week 3-147.70
Week 4-138.40
Week 6-147.30
Week 8-148.10
Week 10-143.50
Week 12-144.30
SecondaryChange-from-baseline Haptoglobin Values

Changes from baseline at each of the scheduled postbaseline time-points

Time frame:
Through week 12
Reported as:
Mean · g/L
Change-from-baseline Haptoglobin Values
g/LZilucoplan (RA101495)
Week 10.000 ± 0.000
Week 20.000 ± 0.000
Week 30.000 ± 0.000
Week 40.133 ± 0.231
Week 60.000 ± 0.000
Week 80.000 ± 0.000
Week 100.000 ± 0.000
Week 120.000 ± 0.000
SecondaryChange-from-baseline Reticulocyte Values

Changes from baseline at each of the scheduled postbaseline time-points

Time frame:
Through week 12
Reported as:
Mean · 10^12 cells/L
Change-from-baseline Reticulocyte Values
10^12 cells/LZilucoplan (RA101495)
Week 1-0.0190 ± 0.0382
Week 20.0090 ± 0.0052
Week 30.0430 ± 0.0327
Week 40.0477 ± 0.0499
Week 60.0310 ± 0.0157
Week 80.0253 ± 0.0248
Week 100.0350 ± 0.0350
Week 120.0190 ± 0.0092
SecondaryChange-from-baseline Hemoglobinuria Values

Changes from baseline at each of the scheduled postbaseline time-points Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10. Where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria.

Time frame:
Through week 12
Reported as:
Mean · score on a scale
Change-from-baseline Hemoglobinuria Values
score on a scaleZilucoplan (RA101495)
Week 10.0
Week 20.5 ± 0.7
Week 30.5 ± 0.7
Week 41.0 ± 1.4
Week 60.5 ± 0.7
Week 82.0
Week 102.3 ± 2.5
Week 12-0.3 ± 2.1

Adverse events

Collected over Through week 12 of the Study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zilucoplan (RA101495)0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Most frequent other events
EventZilucoplan (RA101495)
NauseaGastrointestinal disorders1/3
Influenza like illnessGeneral disorders1/3
Lipase increasedInvestigations1/3
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/3
Pain in extremityMusculoskeletal and connective tissue disorders1/3
HeadacheNervous system disorders1/3
HaemoglobinuriaRenal and urinary disorders1/3
NephrolithiasisRenal and urinary disorders1/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Zilucoplan (RA101495)
<=18 years0
Between 18 and 65 years3
>=65 years0
Age, Continuous
Age, Continuous(years)Zilucoplan (RA101495)
Mean35.3 ± 16.3
Sex: Female, Male
Sex: Female, Male(Participants)Zilucoplan (RA101495)
Female1
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zilucoplan (RA101495)
Hispanic or Latino0
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zilucoplan (RA101495)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White1
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Zilucoplan (RA101495)
United States3
Weight
Weight(kg)Zilucoplan (RA101495)
Mean109.67 ± 13.97
Height
Height(cm)Zilucoplan (RA101495)
Mean176.20 ± 7.60

1 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • Investigative Site
    Duarte, California 91010, United States
  • Investigative Site
    Los Angeles, California 90033, United States
  • Investigative Site
    Chicago, Illinois 60612, United States
  • Investigative Site
    Manhasset, New York 11030, United States
  • Investigative Site
    Durham, North Carolina 27710, United States
  • Investigative Site
    Dallas, Texas 75390, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Mar 2018, 11 months.

Results were first posted in Feb 2020, 1 year 10 months after primary completion.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 11 months is below that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2017
First posted
Jan 24, 2017
StartActual
Apr 17, 2017
Primary completionActual
Mar 28, 2018
CompletionActual
Mar 28, 2018
Results first posted
Feb 26, 2020
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03030183
Lead sponsor
Ra Pharmaceuticals
Responsible party
Sponsor
First posted
Jan 24, 2017
Start date
Apr 17, 2017
Primary completion
Mar 28, 2018
Completion
Mar 28, 2018
Results posted
Feb 26, 2020
Last update
Jul 27, 2022

Study contacts

Dr. Anita Hill
study chair · St James' Institute of Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilucoplan

Start the discussion